FDA warning letters in 2026 continue targeting compounding pharmacies. Telehealth operators, with a notable wave issued June 18, 2026, alongside sustained enforcement against online GLP-1 marketing—facilities. Products must maintain accurate FDA registration and listing to avoid triggering these actions.
Foreign manufacturers lacking a compliant U.S. agent face heightened FDA scrutiny, as 2026 warning letters increasingly cite compounding, telehealth, and labeling violations. We track these enforcement trends and help food, cosmetic, device, and drug companies establish proper registration before FDA identifies gaps. Katherine Giannamore represents clients nationwide and internationally, resolving warning letters and import alert issues before they escalate.
Key Takeaways
- FDA warning letters address compounding and telehealth violations as enforcement priorities in 2026.
- Warning letter recipients must register facilities and list products with FDA compliance requirements.
- Regulatory status of cited issues changes through subsequent FDA and recipient interactions.
- Domestic and foreign drug manufacturers must register and list all commercially marketed products.
What Triggers an FDA Registration Agent Warning Letter?
Missing or lapsed facility registration triggers most warning letters tied to registration failures. Foreign establishments that manufacture, repack, or re-label certain FDA-regulated products for the U.S. market must register with FDA before those products reach American commerce. Skip that step, and enforcement follows quickly.
We help foreign manufacturers avoid that outcome by building compliant registration and listing processes from the start. Our firm handles registration and listing services alongside a broad range of food and drug law matters. Gaps in your paperwork don’t turn into gaps in market access.
Does a Warning Letter Mean My Company Is Currently Out of Compliance?
Not necessarily. Warning letters describe conditions observed at a specific point in time. Matters discussed in a letter often change after further interaction between the company and FDA. A letter posted publicly may no longer reflect where your registration status actually stands, especially if you’ve since corrected the underlying issue.
What Should a Foreign Manufacturer Do After Receiving One?
Respond promptly, and respond with precision. Attorney Katherine Giannamore’s practice covers responses to warning letters as part of a wider scope of regulatory work, including:
- Ingredient and label reviews
- Marketing material reviews, including websites and video advertising
- Registration and listing corrections
- Broader food and drug law counsel
Common triggers we see include:
| Trigger | Consequence |
|---|---|
| Unregistered foreign facility | Product refused entry or flagged for import alert |
| Outdated registration details | FDA correspondence goes unanswered |
| No U.S. agent designated | Delayed communication during an FDA inquiry |
Foreign manufacturers who treat registration as a one-time task, rather than an ongoing obligation, face the highest risk of enforcement letters landing in their inbox.
Why Do Foreign Manufacturers Need a US Agent?
Federal law requires drug manufacturers, repackers, and re-labelers outside the United States to list every commercially marketed drug product with FDA, and a US-based point of contact makes that process possible. Without a reliable domestic presence, foreign companies risk delayed listings, missed FDA correspondence, and enforcement exposure that can halt shipments at the border. A FDA registration agent bridges that gap, giving overseas manufacturers a compliant channel for communication with the agency.
What Does an FDA Registration Agent Actually Do?
An agent serves as the official liaison between a foreign establishment and FDA, receiving inspection notices, communications, and other regulatory correspondence on the manufacturer’s behalf. This role matters most during product listing, facility registration, and any agency inquiry that demands a prompt US response.
Foreign manufacturers entering the American market face more than a single filing requirement. They face a web of overlapping rules across product categories, and missing one step can stall an entire product launch.
We have guided food, beverage, dietary supplement, cosmetic, medical device, and OTC drug companies through FDA compliance nationwide and internationally. Our regulatory counsel covers every FDA-regulated product category, spanning pre-market review through enforcement defense, which matters for companies with no prior US regulatory footprint.
Before a foreign manufacturer ships a single unit, several review steps reduce downstream risk:
- Product formulation and ingredient review against FDA requirements
- Marketing and labeling review for compliance with federal advertising rules
- Facility registration and product listing coordination
- Ongoing agent representation for FDA correspondence
We review products and marketing materials across these industries. Companies build compliance into their US strategy from day one, rather than reacting to an agency letter after the fact.
What Enforcement Trends Are Shaping 2026 Warning Letters?
FDA enforcement in 2026 has reached a midpoint marked by several distinct patterns. Regulated companies watching closely have already spotted where the agency plans to spend the rest of the year. Foreign manufacturers preparing US market entry cannot afford to miss these signals.
Global attention on FDA enforcement has grown throughout the year, drawing comparisons to a widely watched international sporting event. Companies operating across borders face scrutiny no matter where they are headquartered. We track these developments weekly to help clients anticipate risk before a warning letter arrives.
Why is FDA targeting GLP-1 marketing and compounding?
FDA has sustained a crackdown on the marketing and compounding of GLP-1 drugs, particularly semaglutide and tirzepatide. Telehealth companies and online sellers offering these medications sit squarely in the agency’s crosshairs. Several warning letters this year cite unauthorized compounding claims and misleading online promotion. Foreign drug manufacturers supplying ingredients or finished products into this space should expect continued pressure.
Is telehealth compounding still under FDA review?
Yes — FDA has renewed its focus on compounding and telehealth operations, issuing another wave of warning letters targeting this sector. This is not a one-time sweep; it reflects an ongoing enforcement priority. Manufacturers and distributors connected to telehealth-facilitated compounding should reassess labeling, marketing claims, and supply chain documentation now, rather than after receiving a letter.
These trends point to a consistent theme: FDA is watching cross-border operations, digital marketing, and compounding practices with equal intensity. Our regulatory counsel spans pre-market review through enforcement defense, which positions foreign manufacturers to respond quickly as priorities shift. Companies that engage a FDA registration agent. Build compliance review into their launch process reduce exposure well before enforcement activity intensifies further this year.
How Should You Respond to a Warning Letter?
A written, deadline-driven response gives foreign manufacturers and startup teams the best chance of resolving a warning letter without escalation to seizure, injunction, or import detention. Silence or a vague reply costs far more than the time spent drafting a thorough one. FDA reviews the adequacy of the response before deciding its next move. We build every response around the specific violations cited, correcting the record while showing FDA a credible compliance path forward.
What does a warning letter response need to include?
A strong response addresses each violation individually, explains root causes, and documents corrective actions already underway. Generic assurances or promises to “look into it” rarely satisfy FDA reviewers. We draft responses that pair each cited deficiency with concrete evidence: revised labels, updated standard operating procedures, or third-party testing records.
Companies seeking more context behind a warning letter’s findings can also submit an information request directly to FDA. This route helps clarify ambiguous citations before a response is finalized, and it strengthens the accuracy of what gets submitted.
Our regulatory practice extends well beyond letter drafting. We review marketing materials — websites, brochures, video advertisements — alongside formal warning letter responses, since messaging problems often trigger the original citation. Correcting only the label while leaving flawed marketing claims in place invites a second letter.
FDA registration agent support matters here too: foreign establishments must maintain accurate registration and listing information, and errors in that record can complicate a warning letter response. We stand ready seven days a week by phone or email, with responses typically provided within 24 hours, so time-sensitive deadlines don’t slip.
How Can Legal Counsel Prevent Future Violations?
Early legal review, not damage control, prevents most FDA violations before they happen. Shehadeh Giannamore, PLLC works with foreign manufacturers and startup founders to catch compliance gaps in products and marketing materials before regulators ever see them. Waiting until after a warning letter arrives costs companies time, money, and market access they cannot easily recover.
We build compliance into a product’s foundation, not onto it after the fact. Reviewing labeling, ingredient claims, and promotional content at the outset. Launch or before a marketing campaign goes live, helps companies operating in food, cosmetics, medical devices, and drug categories establish a defensible regulatory position from day one. This proactive posture matters even more for companies without US operations. An FDA registration agent and outside counsel often serve as their only line of communication with the agency.
Does the Firm Offer a Free Consultation?
Yes. Companies seeking regulatory guidance before problems escalate can request a free consultation to discuss their product, marketing plans, or existing FDA correspondence. This initial conversation lets us flag risk areas early, when corrective action is far simpler and less costly.
How Do We Reach the Firm With Questions?
Clients reach us seven days a week, by phone or email, with most inquiries answered within 24 hours. For manufacturers and regulatory affairs managers navigating time zones. Tight product launch windows, that responsiveness keeps compliance decisions moving without delay. Prospective clients seeking more detail on retaining regulatory counsel can contact us directly to discuss next steps.
FAQ
What triggers an FDA registration agent warning letter?
Missing or lapsed facility registration triggers most warning letters. ### Does receiving a warning letter mean a company is currently out of compliance?
Not necessarily. Warning letters describe conditions observed at a specific point in time. Matters discussed often change after further interaction between the company and FDA, especially once the underlying issue gets corrected.
Why do foreign manufacturers need a US agent?
Federal law requires drug manufacturers, repackers, and re-labelers outside the United States to list every commercially marketed drug product with FDA, and a US-based point of contact makes that listing process possible.
Conclusion
In closing, FDA registration agent warning letters represent a critical enforcement mechanism that demands proactive compliance from regulated entities. Organizations that prioritize regulatory adherence, maintain accurate documentation, and engage qualified legal counsel substantially reduce their exposure to enforcement action. The complexity of FDA requirements necessitates a strategic approach to product development and marketing—one that anticipates regulatory scrutiny rather than reacting to it. Partnering with experienced FDA counsel positions your business to navigate these challenges effectively and maintain operational integrity.